Comparative study of chronic toxic effects of daunorubicin and doxorubicin in rabbits
Language English Country England, Great Britain Media print
Document type Comparative Study, Journal Article, Research Support, Non-U.S. Gov't
- MeSH
- Daunorubicin toxicity MeSH
- Doxorubicin toxicity MeSH
- Ventricular Dysfunction, Left chemically induced pathology MeSH
- Hemodynamics drug effects MeSH
- Clinical Chemistry Tests MeSH
- Rabbits MeSH
- Kidney drug effects pathology MeSH
- Disease Models, Animal MeSH
- Myocardium pathology MeSH
- Antibiotics, Antineoplastic toxicity MeSH
- Heart drug effects MeSH
- Heart Ventricles drug effects pathology physiopathology MeSH
- Heart Failure chemically induced pathology MeSH
- Body Weight drug effects MeSH
- Toxicity Tests, Chronic MeSH
- Animals MeSH
- Check Tag
- Rabbits MeSH
- Male MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Comparative Study MeSH
- Names of Substances
- Daunorubicin MeSH
- Doxorubicin MeSH
- Antibiotics, Antineoplastic MeSH
This study compares the chronic toxicity of two anthracyclines--daunorubicin and doxorubicin, commonly used for induction of anthracycline cardiomyopathy in the rabbit model. Such a comparative study has not been published until now. Both drugs were administered intravenously to male Chinchilla rabbits in doses at 3 mg/kg (50 mg/m2) once weekly for 10 weeks. Selected biochemical, haematological and cardiovascular parameters and body weights were regularly monitored; additionally, a histological evaluation of heart, kidney and liver was performed at the end of the experiment. In the daunorubicin group, there were marked signs of the progressive development of heart failure, like the significant increases of the pre-ejection period/left ventricular ejection time index values (up to 134%)--and histological changes within the myocardium were also observed. On the other hand, the 10-week doxorubicin administration did not cause these changes that are typical for heart injury. Haematotoxicity, manifested particularly by aplastic anaemia, was apparent in both the experimental groups. Significant body weight loss (by 45.2%) and high premature mortality (100% versus 36.4%) reflected a greater general toxicity, especially nephrotoxicity of doxorubicin in comparison with daunorubicin. Further studies are necessary to find a possible explanation for these findings.
References provided by Crossref.org